Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Allogeneic hematopoietic stem cell transplant remains a critical curative option for high-risk blood cancers and selected immune disorders. In 2024, 21,023 allogeneic procedures were recorded across 53 EBMT countries, reflecting sustained clinical use. The allogeneic hematopoietic stem cell transplant pipeline analysis by Expert Market Research highlights progress in graft engineering, regulatory T-cell therapies, safer conditioning regimens, donor expansion, and relapse prevention strategies designed to reduce graft-versus-host disease, improve immune recovery, and extend long-term survival across adult and pediatric patient populations.
-
Major companies involved in the allogeneic hematopoietic stem cell transplant pipeline analysis include StemCyte Taiwan Co., Ltd., BioSpring Medical Co., Ltd., and others.
-
Leading drugs currently in the pipeline include TSC-101, MC0518, and others.
-
Growing adoption of targeted conditioning strategies and graft-versus-host disease prevention technologies is driving pipeline expansion in allogeneic hematopoietic stem cell transplant. Increasing investment in donor-specific immune modulation, engineered cellular therapies, and precision biologics is accelerating innovation aimed at improving engraftment success, reducing transplant-related toxicity, and enhancing long-term patient outcomes.
Report Coverage
The Allogeneic Hematopoietic Stem Cell Transplant Pipeline Analysis Report by Expert Market Research gives comprehensive insights into allogeneic hematopoietic stem cell transplant therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for allogeneic hematopoietic stem cell transplant. The allogeneic hematopoietic stem cell transplant report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The allogeneic hematopoietic stem cell transplant pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with allogeneic hematopoietic stem cell transplant treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to allogeneic hematopoietic stem cell transplant.
Read more about this report - Request a Free Sample
Allogeneic Hematopoietic Stem Cell Transplant Pipeline Outlook
The Allogeneic Hematopoietic Stem Cell Transplant pipeline is advancing through improved conditioning regimens, graft engineering, immune modulation, and supportive therapies designed to reduce relapse, infections, and graft-versus-host disease. For instance, in June 2026, the US FDA approved TREGZI, developed by Orca Bio, for adults with hematologic malignancies undergoing matched-donor transplantation. The regulatory T-cell-based immunotherapy supports hematopoietic and immune reconstitution and improves chronic graft-versus-host disease-free survival following intensive myeloablative preparative treatment protocols, marking a major step toward safer and more effective transplant outcomes.
Allogeneic Hematopoietic Stem Cell Transplant Epidemiology
Latest registry data show sustained growth in allogeneic hematopoietic stem cell transplantation. In 2024, the EBMT recorded 21,023 allogeneic procedures across 53 countries, a 2.6% increase from 2023 and the highest annual activity reported. Myeloid malignancies accounted for 62% of European procedures, with acute myeloid leukemia remaining the leading indication. The United States reported 10,402 related and unrelated donor transplants in 2024. Rising use of unrelated and haploidentical donors is expanding access, though regional differences in transplant availability remain substantial.
Allogeneic Hematopoietic Stem Cell Transplant – Pipeline Therapeutic Assessment
This section of the report covers the analysis of allogeneic hematopoietic stem cell transplant drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The allogeneic hematopoietic stem cell transplant pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Cell Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Allogeneic Hematopoietic Stem Cell Transplant Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total allogeneic hematopoietic stem cell transplant clinical trials. Phase II (45.66%), Phase I (38.33%) Early Phase I (6.81%) Phase III (7.16%) Phase IV (2.04%).
Allogeneic Hematopoietic Stem Cell Transplant Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the allogeneic hematopoietic stem cell transplant pipeline analysis include small molecules, monoclonal antibodies, and cell therapies. The allogeneic hematopoietic stem cell transplant report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for allogeneic hematopoietic stem cell transplant. In January 2025, the US FDA approved GRAFAPEX, or treosulfan, in combination with fludarabine as a preparative regimen before allogeneic hematopoietic stem cell transplantation.
Allogeneic Hematopoietic Stem Cell Transplant Clinical Trials – Key Players
The EMR report for the allogeneic hematopoietic stem cell transplant pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed allogeneic hematopoietic stem cell transplant therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in allogeneic hematopoietic stem cell transplant clinical trials:
- Orca Biosystems, Inc.
- Chengdu Ucello Biotechnology Co., Ltd.
- Nuwacell Biotechnologies Co., Ltd.
- Guangdong ProCapZoom Biosciences Co., Ltd.
- Poseida Therapeutics, Inc.
- Caribou Biosciences, Inc.
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
- Hangzhou Qihan Biotech Co., Ltd.
- Restem, LLC
- StemCyte Taiwan Co., Ltd.
- BioSpring Medical Co., Ltd.
- Arovella Therapeutics Ltd.
Allogeneic Hematopoietic Stem Cell Transplant – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for allogeneic hematopoietic stem cell transplant. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of allogeneic hematopoietic stem cell transplant drug candidates.
Drug: TSC-101
TSC-101 is a precision monoclonal antibody developed by TScan Therapeutics to improve outcomes following allogeneic hematopoietic stem cell transplant (HSCT). It selectively targets recipient hematopoietic cells expressing HLA-A*02, facilitating donor stem cell engraftment while reducing conditioning-related toxicity and preserving healthy tissues. The ongoing Phase 1 study is expected to reach primary completion in 2027. TScan Therapeutics is a U.S.-based biotechnology company specializing in T-cell receptor–driven immunotherapies and innovative immune-engineering technologies.
Biological: MC0518
MC0518 is an investigational cell therapy (biological) being developed by Medac/Medac Gesellschaft für klinische Spezialpräparate mbH for patients undergoing allogeneic hematopoietic stem cell transplant. The therapy is designed to promote immune reconstitution and reduce transplant-related complications by supporting balanced immune recovery following donor stem cell infusion. The current clinical study is expected to be completed in 2027. Medac is a Germany-based pharmaceutical company with extensive expertise in hematology, oncology, transplantation, and immunology.
Drug: allo-APZ2-CVU
allo-APZ2-CVU is an investigational cell therapy developed by Apmonia Therapeutics for use alongside allogeneic hematopoietic stem cell transplant. It is designed to enhance immune regulation and reduce the risk of graft-versus-host disease while preserving beneficial graft-versus-leukemia activity, supporting improved transplant success. The ongoing early-stage clinical program is expected to reach completion in 2028. Apmonia Therapeutics is a biotechnology company focused on developing advanced cellular immunotherapies for transplantation and immune-mediated disorders.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Allogeneic Hematopoietic Stem Cell Transplant Pipeline Insight Report
- Which companies/institutions are leading the allogeneic hematopoietic stem cell transplant drug development?
- Which company is leading the allogeneic hematopoietic stem cell transplant pipeline development activities?
- What is the current allogeneic hematopoietic stem cell transplant commercial assessment?
- What are the opportunities and challenges present in the allogeneic hematopoietic stem cell transplant pipeline landscape?
- What is the efficacy and safety profile of allogeneic hematopoietic stem cell transplant pipeline drugs?
- Which company is conducting major trials for allogeneic hematopoietic stem cell transplant drugs?
- Which companies/institutions are involved in allogeneic hematopoietic stem cell transplant collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in allogeneic hematopoietic stem cell transplant?
Reasons To Buy This Report
The Allogeneic Hematopoietic Stem Cell Transplant Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for allogeneic hematopoietic stem cell transplant. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into allogeneic hematopoietic stem cell transplant collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
